CN115279394A - 用于放射治疗的预防性皮肤治疗 - Google Patents

用于放射治疗的预防性皮肤治疗 Download PDF

Info

Publication number
CN115279394A
CN115279394A CN202080093822.2A CN202080093822A CN115279394A CN 115279394 A CN115279394 A CN 115279394A CN 202080093822 A CN202080093822 A CN 202080093822A CN 115279394 A CN115279394 A CN 115279394A
Authority
CN
China
Prior art keywords
dfo
skin
irradiation
treatment
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093822.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·C·万
M·T·朗克
G·C·格特纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN115279394A publication Critical patent/CN115279394A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080093822.2A 2019-11-20 2020-10-20 用于放射治疗的预防性皮肤治疗 Pending CN115279394A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962938209P 2019-11-20 2019-11-20
US62/938,209 2019-11-20
PCT/US2020/056421 WO2021101646A1 (en) 2019-11-20 2020-10-20 Prophylactic skin treatment for radiation therapy

Publications (1)

Publication Number Publication Date
CN115279394A true CN115279394A (zh) 2022-11-01

Family

ID=75980773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093822.2A Pending CN115279394A (zh) 2019-11-20 2020-10-20 用于放射治疗的预防性皮肤治疗

Country Status (6)

Country Link
US (2) US12403106B2 (enExample)
EP (1) EP4061402A4 (enExample)
JP (2) JP2023503283A (enExample)
CN (1) CN115279394A (enExample)
BR (1) BR112022009804A2 (enExample)
WO (1) WO2021101646A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025111378A1 (en) * 2023-11-20 2025-05-30 Tautona Group Ip Holding Company, L.L.C. Semi-solid formulations of deferoxamine for the treatment of radiation therapy burns

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020727A2 (en) * 2004-08-13 2006-02-23 Healthpartners Research Foundation Methods for treating cns disorders by administration of agents to the nasal cavity
US20170281570A1 (en) * 2008-10-10 2017-10-05 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of hif-1 modulators to prevent and treat chronic wounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE26914C (de) 1883-06-19 1884-05-08 CH E. SACKETT in Wayne-Township, Pennsylvanien, V. St. A Ackergeräth zum Pflügen und Zerkleinern der Erde
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US8303973B2 (en) 2004-09-17 2012-11-06 Angiotech Pharmaceuticals (Us), Inc. Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
WO2006078717A2 (en) 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
CA2947330C (en) 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20100068279A1 (en) 2006-11-28 2010-03-18 Ats Biotech Inc. Burn bandage
CA2697043A1 (en) 2007-08-21 2009-02-26 Virginia Commonwealth University Intellectual Property Foundation Methods and compositions for treatment or prevention of radiation-induced fibrosis
US20090198332A1 (en) 2008-02-05 2009-08-06 Hilton Becker Method for texturing the surface of a synthetic implant
AU2010286054B2 (en) 2009-08-19 2016-10-27 Mordechai Chevion Desferrioxamine-metal complexes for the treatment of immune-related disorders
US8377062B2 (en) 2009-12-17 2013-02-19 Stryker Trauma Gmbh Therapeutic agent capsule for implants
US20140377320A1 (en) 2011-12-22 2014-12-25 Chuv, Centre Hospitalier Universitaire Vaudois Selective Plasma Activation for Medical Implants and Wound Healing Devices
US9737395B2 (en) 2015-06-26 2017-08-22 Phi Nguyen Systems and methods for reducing scarring
US10933174B2 (en) 2016-05-03 2021-03-02 Medtronic, Inc. Hemostatic devices and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020727A2 (en) * 2004-08-13 2006-02-23 Healthpartners Research Foundation Methods for treating cns disorders by administration of agents to the nasal cavity
US20170281570A1 (en) * 2008-10-10 2017-10-05 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of hif-1 modulators to prevent and treat chronic wounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABRA H. SHEN ET AL: "Prophylactic treatment with transdermal deferoxamine mitigates radiation‑induced skin fibrosis", 《SCIENTIFIC REPORTS》, vol. 10, 23 July 2020 (2020-07-23), pages 1 - 11, XP055828135, DOI: 10.1038/s41598-020-69293-4 *
ALICIA E. SNIDER ET AL: "Topical Deferoxamine Alleviates Skin Injury and Normalizes Atomic Force Microscopy Patterns Following Radiation in a Murine Breast Reconstruction Model", 《ANN PLAST SURG.》, vol. 81, no. 5, 1 November 2019 (2019-11-01), pages 604 - 608, XP093094476, DOI: 10.1097/SAP.0000000000001592 *
JOHN FLACCO, BS ET AL: "Deferoxamine Preconditioning of Irradiated Tissue Improves Perfusion and Fat Graft Retention", 《PLAST RECONSTR SURG》, vol. 141, no. 3, 1 March 2019 (2019-03-01), pages 655 - 665, XP055828131, DOI: 10.1097/PRS.0000000000004167 *
李佳;邢志伟;于程程;姜恩海;: "放射性皮肤损伤研究进展", 中华临床医师杂志(电子版), no. 06, 15 March 2013 (2013-03-15) *

Also Published As

Publication number Publication date
JP2023503283A (ja) 2023-01-27
US20220409559A1 (en) 2022-12-29
JP2025084944A (ja) 2025-06-03
BR112022009804A2 (pt) 2022-08-16
US12403106B2 (en) 2025-09-02
EP4061402A4 (en) 2023-12-06
US20250375400A1 (en) 2025-12-11
WO2021101646A1 (en) 2021-05-27
EP4061402A1 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
Chen et al. Layered GelMA/PEGDA hydrogel microneedle patch as an intradermal delivery system for hypertrophic scar treatment
Flacco et al. Deferoxamine preconditioning of irradiated tissue improves perfusion and fat graft retention
US20250262176A1 (en) Conditioning Irradiated Tissue for Increasing Vascularity
Duan et al. ZIF-8 as a protein delivery system enhances the application of dental pulp stem cell lysate in anti-photoaging therapy
Li et al. Sulforaphane promotes white matter plasticity and improves long-term neurological outcomes after ischemic stroke via the Nrf2 pathway
US20250375400A1 (en) Prophylactic skin treatment for radiation therapy
Ohshima et al. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia–ischemia
US20200330738A1 (en) GENE SILENCING IN SKIN USING SELF-DELIVERY siRNA DELIVERED BY A MESO DEVICE
He et al. Microneedles combining delivery of hUMSC-derived exosomes and EGCG mitigate UV-induced skin damage
Mericli et al. Deferoxamine mitigates radiation-induced tissue injury in a rat irradiated TRAM flap model
Yu et al. Exendin-4 promotes ischemia-reperfusion flap survival by upregulating Gpx4 to inhibit ferroptosis
Diao et al. CD147 inhibition reduced fibronectin expression in TGF-β1-induced keloid fibroblasts by targeting Smad2 signaling pathway
US20250152649A1 (en) Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair
Tang et al. Stem cells enhance reperfusion following ischemia: Validation using laser speckle imaging in predicting tissue repair
CN106822093B (zh) 组合物用于制备血管新生异常的药物的用途
Brewer et al. Multiphoton imaging of excised normal skin and keloid scar: preliminary investigations
Yan et al. Qinglongyi nanoparticles alleviate neuroinflammation and promote neuronal survival by inhibiting neuronal ferroptosis in intracerebral hemorrhage
Shafik et al. Treatment of atrophic acne scars with platelet rich plasma gel and micro-needling
Morgun et al. The Model of an Ischemic Non-Healing Wound: Regeneration after Transplantation of a Living Skin Equivalent
Palomba et al. Enhancing Tumor Perfusion and Nanomedicine Delivery via Endogenous Nitric Oxide Release by Methyl Palmitate Nanoparticles
NESSA Evaluation of the effects of pre-injury exercise in a mouse hindlimb model of secondary lymphedema
Zhang et al. Development of perilla essential oil-based nanoemulsions as anti-psoriatic and dermal delivery platforms for topical therapy
CN108186675A (zh) 肝素铁复合物对慢性炎症性贫血的治疗应用
Adel et al. Histological and Biochemical study on the accelerating effect of non-cross linked hyaluronic acid and polydioxanone smooth threads on wound healing in adult albino rats.
Wang et al. Novel Barbed Microneedle Array‐Mediated Dual‐Drug Delivery for Thick Infantile Hemangiomas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination